Skip to main content
BFRI logo

BFRI · Biofrontera Inc.

Track BFRI — free
$1.55 +0.09 (+6.16%) At close · Sep 11
Market Cap
$23.17M
Shares
14.85M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.55 Open$1.54 Day$1.50–1.62 52W close$0.57–1.61 Avg vol 30d642K Short int255K · 1.7% float · 1.0d Short vol46% Last earningsAug 13, 2026 DataJul 2023–Sep 2026 Filing10-Q · Aug 13

Raw chart and full-history price indicators begin at the captured split on Jul 5, 2023; bars on opposite sides are not compared.

Up next

Next earnings call
Nov 13, 2026 Est · unconfirmed · in 9 wks
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$46.17M
Trailing 12 months
Net income (TTM)
−$6.37M
Trailing 12 months
Revenue growth YoY
+32.9%
Year over year
Operating margin
-14.2%
Trailing 12 months
P / E (TTM)
Trailing earnings
FCF yield
TTM · current market cap
Return on invested capital
Trailing 12 months
Net cash
Latest balance sheet
Dividend yield
Trailing 12 months
Shares change YoY
+38.2%
Year over year · more shares
Price change (1Y)
+74.6%
Trailing year
Short interest
1.7%
Latest settlement · 1.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +56%
above
Price vs 50-day avg +21%
above
RSI (14) 60
neutral
MACD trend Negative
52-week position 94%
near high
Momentum
relative strength
Very Strong
1-month return +23%
trailing
6-month return +78%
trailing
YTD return +172%
this year
Relative strength +60%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Accumulating
+44% holders QoQ · +9 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.72% of float · ▲ +675.7% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
23 holders — near 3-yr high, broad support
Squeeze score 65
elevated · 0–100
Fundamentals
Strong
Revenue growth +19%
Y/Y
EPS growth +68%
Y/Y
Free cash flow $-13.4M
Quant / Vol
risk profile
Very High
Volatility 78%
annualized · 1-yr
Max drawdown −51%
past year
ATR 6.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Prior guidance period ended · from the 8-K filed Jan 13, 2026
Revenues · fourth quarter ended December 31, 2025 $17M – $17.5M
Revenues · full year 2025 $41.5M – $42M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+56% Bullish
Price vs 50-day avg
+21% Bullish
RSI (14)
60 Neutral
MACD trend
Negative Bearish
52-week position
94% Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Accumulating
+44% holders QoQ · +9 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.72% of float · ▲ +675.7% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
23 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $2 · 94% Range high $2
vs 200-day avg +56% vs 50-day avg +21%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BFRI
Biofrontera Inc.
this stock
$23.17M +171.9% +19.0% 1.7%
TAK
Takeda Pharmaceutical Co Ltd
$58.31B +17.1% 0.1%
GALDY
Galderma Group AG/ADR
$44.03B -8.9% 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$43.22B +18.8% +4.3% 60.8 3.2%
HLN
Haleon plc
$40.41B -9.1% 0.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
23
% held
19.7%
Net QoQ
+323.7K sh
Top holder
Rosalind Advisors, Inc.
Held Float
View
Held by Funds
Fund positions
4
View
Short & Settlement
Short Interest Rising
Shares short
255.3K
Days to cover
1.0d
Change
+222.4K sh
View
Short Volume
Short vol %
46%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
20.5K
Value
$23.4K
As of
Jul 9, 2026
View
Off-Exchange
Off-exchange %
66.8%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$41.7M
Net income (FY)
$-10.5M
EPS diluted
$-1.04
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 13, 2026
This year
14
View
Exempt Offerings
Offering
$11.0M
Filed
Jul 11, 2025
View
Earnings & Events
Earnings Calls
Last call
Aug 13, 2026
View

Performance

Raw-price comparisons begin at the captured split on Jul 5, 2023; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
BFRI +2.7% +23.0% +78.2% +1.3% +171.9%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY +3.8% +24.8% +60.3% +1.7% +159.9%
Key facts CIK 1858685 CUSIP 09077D209 13F (30d) 12 filings 12 filers Visit website Investor relations